Managing the oncologic patient with suspected pneumonia in the intensive care unit

References

• Jules-Elysee K, Stover DE, Yahalom J, et al. Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation. Am Rev Respir Dis. 1992;146:485–491.
   PubMed Web of Science ®Google Scholar
• Chaoui D, Legrand O, Roche N, et al. Incidence and prognostic value of respiratory events in acute leukemia. Leukemia. 2004;18:670–675.
   PubMed Web of Science ®Google Scholar
• Agustì C, Lucena C, Torres C. Epidemiology of acute respiratory failure in patients with HM (ICU Only). In: Azoulay E, editor. Pulmonary involvement in patients with haematological malignancies. Vol. 5. Milan: Springer; 2011. p. 47–55.
   Google Scholar
• Azoulay E, Thiéry G, Chevret S, et al. The prognosis of acute respiratory failure in critically ill cancer patients. Medicine (Baltimore). 2004;83:360–370.
   PubMed Web of Science ®Google Scholar
• Taccone FS, Artigas AA, Sprung CL, et al. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13:R15.
   PubMed Web of Science ®Google Scholar
• Bos MM, De Keizer NF, Meynaar IA, et al. Outcomes of cancer patients after unplanned admission to general intensive care units. Acta Oncol. 2012;51:897–905.
   PubMed Web of Science ®Google Scholar
• Soares M, Caruso P, Silva E, et al. Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit Care Med. 2010;38:9–1.
   PubMed Web of Science ®Google Scholar
• Puxty K, McLoone P, Quasim T, et al. Risk of critical illness among patients with solid cancers: a population-based observational study. JAMA Oncol. 2015;1:1078–1085.
   PubMed Web of Science ®Google Scholar
• Wallace SK, Rathi NK, Waller DK, et al. Two Decades of ICU Utilization and Hospital Outcomes in a Comprehensive Cancer Center. Crit Care Med. 2016;44:926–933.
   PubMed Web of Science ®Google Scholar
• Hawari FI, Nazer LH, Addassi A, et al. Predictors of ICU admission in patients with cancer and the related characteristics and outcomes: a 5-year registry-based study. Crit Care Med. 2016;44:548–553.
   PubMed Web of Science ®Google Scholar
• Bos MM, Verburg IW, Dumaij I, et al. Intensive care admission of cancer patients: a comparative analysis. Cancer Med. 2015;4:966–976.
   PubMed Web of Science ®Google Scholar
• Park SY, Lim SY, Um SW, et al. Outcome and predictors of mortality in patients requiring invasive mechanical ventilation due to acute respiratory failure while undergoing ambulatory chemotherapy for solid cancers. Support Care Cancer. 2013;21:1647–1653.
   PubMed Web of Science ®Google Scholar
• Schnell D, Mayaux J, Lambert J, et al. Clinical assessment for identifying causes of acute respiratory failure in cancer patients. Eur Respir J. 2013;42:435–443.
   PubMed Web of Science ®Google Scholar
• Rabello LS, Silva JR, Azevedo LC, et al. Clinical outcomes and microbiological characteristics of severe pneumonia in cancer patients: a prospective cohort study. PLoS One. 2015 24;10(3):e0120544.
   Web of Science ®Google Scholar
• Azevedo LC, Caruso P, Silva UV, et al. Outcomes for patients with cancer admitted to the ICU requiring ventilatory support: results from a prospective multicenter study. Chest. 2014;146:257–266.
   PubMed Web of Science ®Google Scholar
• Heo SJ, Kim G, Lee CK, et al. Prediction of short- and long-term survival for advanced cancer patients after ICU admission. Support Care Cancer. 2015;23:1647–1655.
   PubMed Web of Science ®Google Scholar
• Souza-Dantas MA, Salluh JIF, Soares M. Impact of neutropenia on the outcomes of critically ill patients with cancer: a matched case–control study. Ann Oncol. 2011;22:2094–2100.
   PubMed Web of Science ®Google Scholar
• Mokart D, Darmon M, Resche-Rigon M, et al. Prognosis of neutropenic patients admitted to the intensive care unit. Intensive Care Med. 2015;41:296–303.
   PubMed Web of Science ®Google Scholar
• Darmon M, Azoulay E, Alberti C, et al. Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med. 2002;28:1775–1780.
   PubMed Web of Science ®Google Scholar
• Kurtin S. Myeloid toxicity of cancer treatment. J Adv Pract Oncol. 2012;3:209–224.
   PubMedGoogle Scholar
• Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist. 1998;3:446–451.
   PubMedGoogle Scholar
• Marín M, Gudiol C, Garcia-Vidal C, et al. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine. 2014;93::143–149.
   PubMed Web of Science ®Google Scholar
• Yan X, Li M, Jiang M, et al. Clinical characteristics of 45 patients with invasive pulmonary aspergillosis: retrospective analysis of 1711 lung cancer cases. Cancer. 2009;115:5018–5025.
   PubMed Web of Science ®Google Scholar
• Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in haematologic malignancy. Cancer. 2008;112:2493–2499.
   PubMed Web of Science ®Google Scholar
• Moosa MY, Sobel JD. Non-albicans Candida infections in patients with haematologic malignancies. Semin Respir Infect. 2002;17:91–98.
   PubMedGoogle Scholar
• Seo JB, Im JG, Goo JM, et al. Atypical pulmonary metastases: spectrum of radiologic findings. Radiographics. 2001;21:403–417.
   PubMed Web of Science ®Google Scholar
• Camus P, Fanton A, Bonniaud P, et al. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71:301–326.
   PubMed Web of Science ®Google Scholar
• Bonavita E, Galdiero MR, Jaillon S, et al. Phagocytes as corrupted policemen in cancer-related inflammation. Adv Cancer Res. 2015;128:141–171.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Park JS, Kim DW, et al. Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients. Respir Med. 2012;106:443–450.
   PubMed Web of Science ®Google Scholar
• Anderson JE. Respiratory infections. Cancer Treat Res. 2014;161:203–236.
   PubMedGoogle Scholar
• Fujita T, Endo M, Gu Y, et al. Mycobacterium tuberculosis infection in cancer patients at a tertiary care cancer center in Japan. J Infect Chemother. 2014;20:213–216.
   PubMed Web of Science ®Google Scholar
• Shander A, Popovsky MA. Understanding the consequences of transfusion-related acute lung injury. Chest. 2005;128(Suppl 5):598S–604S.
   Google Scholar
• Shune SE, Karnell LH, Karnell MP, et al. Association between severity of dysphagia and survival in patients with head and neck cancer. Head Neck. 2012;34:776–784.
   PubMed Web of Science ®Google Scholar
• Akinosoglou KS, Karkoulias K, Marangos M, et al. Infectious complications in patients with lung cancer. Eur Rev Med Pharmacol Sci. 2013;17:8–18.
   PubMed Web of Science ®Google Scholar
• Sarihan S, Ercan I, Saran A, et al. Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy. Cancer Detect Prev. 2005;29:181–188.
   PubMedGoogle Scholar
• Mei J, Liu L, Tang M. Airway bacterial colonization in patients with non-small cell lung cancer and the alterations during the perioperative period. J Thorac Dis. 2014;6:1200–1208.
   PubMed Web of Science ®Google Scholar
• Venditti M, Falcone M, Corrao S, et al. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150:19–26.
   PubMed Web of Science ®Google Scholar
• Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2016 [ cited Jun 10]; DOI:10.1007/s10096-016-2703-z.
   PubMedGoogle Scholar
• Belda J, Cavalcanti M, Ferrer M, et al. Bronchial colonization and postoperative respiratory infections in patients undergoing lung cancer surgery. Chest. 2005;128:1571–1579.
   PubMed Web of Science ®Google Scholar
• Montassier E, Batard E, Gastinne T, et al. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32:841–850.
   PubMed Web of Science ®Google Scholar
• González C, Rubio M, Romero-Vivas J, et al. Staphylococcus aureus bacteremic pneumonia: differences between community and nosocomial acquisition. Int J Infect Dis. 2003;7:102–108.
   PubMedGoogle Scholar
• Wang SS, Lee NY, Hsueh PR, et al. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Microbiol Immunol Infect. 2011;44:282–288.
   PubMedGoogle Scholar
• Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65:333–341.
   PubMed Web of Science ®Google Scholar
• Bos MM, Smeets LS, Dumay I, et al. Bloodstream infections in patients with or without cancer in a large community hospital. Infection. 2013;41:949–958.
   PubMed Web of Science ®Google Scholar
• Williams MD, Braun LA, Cooper LM, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care. 2004;8:R291–8.
   PubMed Web of Science ®Google Scholar
• Vallés J, Alvarez-Lerma F, Palomar M, et al. Health-care-associated bloodstream infections at admission to the ICU. Chest. 2011;139:810–815.
   PubMed Web of Science ®Google Scholar
• Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38:1930–1945.
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose CE Jr, Fry AM. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–386.
   PubMed Web of Science ®Google Scholar
• Naucler P, Darenberg J, Morfeldt E, et al. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax. 2013;68:571–579.
   PubMed Web of Science ®Google Scholar
• Wong A, Marrie TJ, Garg S, et al. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infec. 2010;138:1804–1810.
   PubMed Web of Science ®Google Scholar
• Aliberti S, Myers JA, Peyrani P, et al. The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia. Eur Respir J. 2009;33:142–147.
   PubMed Web of Science ®Google Scholar
• Aisenberg G, Rolston KV, Dickey BF, et al. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997–2004. Eur J Clin Microbiol Infect Dis. 2007;26:13–20.
   PubMed Web of Science ®Google Scholar
• Kang CI, Song JH, Ko KS, et al. Asian Network for Surveillance of Resistant Pathogens Study Group. Clinical features and outcomes of Staphylococcus aureus infections in non-neutropenic cancer patients. Support Care Cancer. 2012;20:483–488.
   PubMed Web of Science ®Google Scholar
• Li MC, Lee NY, Lee CC, et al. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect. 2014;47:42–47.
   PubMedGoogle Scholar
• Bollée G, Sarfati C, Thiéry G, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132:1305–1310.
   PubMed Web of Science ®Google Scholar
• Sokulska M, Kicia M, Wesołowska M, et al. Pneumocystis jirovecii-from a commensal to pathogen: clinical and diagnostic review. Parasitol Res. 2015;114:3577–3585.
   PubMed Web of Science ®Google Scholar
• Waks AG, Tolaney SM, Galar A, et al. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat. 2015;154:359–367.
   PubMed Web of Science ®Google Scholar
• Shinohara T, Yasui M, Yamada H, et al. Pneumocystis pneumonia during postoperative adjuvant chemotherapy for breast cancer. Case Rep Oncol Med. 2013;2013:954346.
   PubMedGoogle Scholar
• Loron MC, Grange S, Guerrot D, et al. Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma. J Clin Oncol. 2015;33:e45–7.
   Google Scholar
• Saito Y, Nagayama M, Miura Y, et al. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma. Jpn J Clin Oncol. 2013;43:559–562.
   PubMed Web of Science ®Google Scholar
• Carbonnaux M, Molin Y, Souquet PJ, et al. Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors. Invest New Drugs. 2014;32:1308–1310.
   PubMed Web of Science ®Google Scholar
• Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol. 2012;12(5):325–338.
   PubMed Web of Science ®Google Scholar
• Chen A, Chen L, Al-Qaisi A, et al. Everolimus-induced haematologic changes in patients with metastatic breast cancer. Clin Breast Cancer. 2015;15:48–53.
   PubMed Web of Science ®Google Scholar
• Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014;44:1350–1363.
   PubMed Web of Science ®Google Scholar
• De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Crit Rev Oncol Haematol. 2013;85:373–382.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Nagai Y, Morita T, et al. Pneumocystis pneumonia in patients treated with long-term steroid therapy for symptom palliation: a neglected infection in palliative care. Am J Hosp Palliat Care. 2014;31:857–861.
   PubMed Web of Science ®Google Scholar
• Caselli D, Petris MG, Rondelli R, et al. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr. 2014;164:389–92.e1.
   PubMed Web of Science ®Google Scholar
• Worth LJ, Dooley MJ, Seymour JF, et al. An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer. 2005;92:867–872.
   PubMed Web of Science ®Google Scholar
• Vinograd I, Eliakim-Raz N, Farbman L, et al. Clinical effectiveness of seasonal influenza vaccine among adult cancer patients. Cancer. 2013;119:4028–4035.
   PubMed Web of Science ®Google Scholar
• Van Kerkhove MD, Cooper MJ, Cost AA, et al. Risk factors for severe outcomes among members of the United States military hospitalized with pneumonia and influenza, 2000–2012. Vaccine. 2015;33:6970–6976.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Vigil KJ, Saad M, et al. A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes. Cancer. 2012;118:4627–4633.
   PubMed Web of Science ®Google Scholar
• Hajjar LA, Mauad T, Galas FR, et al. Severe novel influenza A (H1N1) infection in cancer patients. Ann Oncol. 2010;21:2333–2341.
   PubMed Web of Science ®Google Scholar
• McQuade B, Blair M. Influenza treatment with oseltamivir outside of labeled recommendations. Am J Health Syst Pharm. 2015;72:112–116.
   PubMed Web of Science ®Google Scholar
• Waqar SN, Boehmer L, Morgensztern D, et al. Immunogenicity of influenza vaccination in patients with cancer. Am J Clin Oncol. 2015 [cited 2015 Dec 14]; DOI:10.1097/COC.0000000000000257.
   Web of Science ®Google Scholar
• Hicks KL, Chemaly RF, Kontoyiannis DP. Common community respiratory viruses in patients with cancer : more than just “common colds”. Cancer. 2003;97:2576–2587.
   PubMed Web of Science ®Google Scholar
• Schlick K, Grundbichler M, Auberger J, et al. Cytomegalovirus reactivation and its clinical impact in patients with solid tumors. Infect Agent Cancer. 2015;10:45.
   PubMedGoogle Scholar
• Aisenberg GM, Torres HA, Chemaly RF, et al. Herpes simplex virus lower respiratory tract infection in patients with solid tumors. Cancer. 2009;115:199–206.
   PubMed Web of Science ®Google Scholar
• Cunha BA, Syed U, Mikail N. Bronchoalveolar carcinoma (adenocarcinoma) mimicking recurrent bacterial community-acquired pneumonia (CAP). Heart Lung. 2012;41:83–86.
   PubMed Web of Science ®Google Scholar
• Taus A, Zuccarino F, Trampal C, et al. EGFR-mutant lung adenocarcinoma mimicking a pneumonia. Case Rep Pulmonol. 2012;2012:257827.
   PubMedGoogle Scholar
• Ishii T, Goto Y, Matsuzaki H, et al. Pulmonary metastasis of combined hepatocellular and cholangiocarcinoma: a unique radiographic presentation with air-space consolidation masquerading as pneumonia and primary pulmonary adenocarcinoma. Intern Med. 2015;54:1389–1392.
   PubMed Web of Science ®Google Scholar
• Filippini A, Zorzi F, Bna’ C, et al. Dark sputum: an atypical presentation of primary pulmonary malignant melanoma. Respir Med Case Rep. 2015;15:118–120.
   PubMedGoogle Scholar
• Hamada T, Yasunaga H, Nakai Y, et al. Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study. Respirology. 2016;21:338–343.
   PubMed Web of Science ®Google Scholar
• Kumasawa F, Miura T, Takahashi T, et al. A case of miriplatin-induced lung injury. J Infect Chemother. 2016;22:486–489.
   PubMedGoogle Scholar
• Pankowska-Supryn M, Załęska M, Roszkowska-Śliż B, et al. Interstitial lung disease associated with docetaxel in a patient treated for breast cancer – a case report. Pneumonol Alergol Pol. 2015;83:378–382.
   PubMedGoogle Scholar
• Yan J, Wang C, Zhang Q, et al. A case of methylprednisolone treatment for interstitial pneumonia induced by gefitinibin. Int J Clin Exp Med. 2015;8:14150–14153.
   PubMed Web of Science ®Google Scholar
• Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J. 2003;22:179–181.
   PubMed Web of Science ®Google Scholar
• Guilleminault L, Carre P, Diot P. Hypersensitivity pneumonitis associated with temozolomide. Eur Respir J. 2009;34:526.
   PubMed Web of Science ®Google Scholar
• Kim TO, Oh IJ, Kang HW, et al. Temozolomide-associated bronchiolitis obliterans organizing pneumonia successfully treated with high-dose corticosteroid. J Korean Med Sci. 2012;27:450–453.
   PubMed Web of Science ®Google Scholar
• Yoshii N, Suzuki T, Nagashima M, et al. Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports. Anticancer Drugs. 2011;22:563–568.
   PubMed Web of Science ®Google Scholar
• Koschel D, Handzhiev S, Leucht V, et al. Hypersensitivity pneumonitis associated with the use of temozolomide. Eur Respir J. 2009;33:931–934.
   PubMed Web of Science ®Google Scholar
• Nishino M, Brais LK, Brooks NV, et al. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. Eur J Cancer. 2016;53:163–170.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Chatzaki E, Porpodis K, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine. 2012;7:1551–1572.
   PubMed Web of Science ®Google Scholar
• Gagnadoux F, Hureaux J, Vecellio L, et al. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv. 2008;21(1):61–70.
   PubMed Web of Science ®Google Scholar
• Verschraegen FC, Gilbert EB, Loyer E, et al. clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res. 2004;10:2319–2326.
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Saad M, Pozharov VP, et al. Inhibition of lung tumor growth by complex pulmonary delivery ofdrugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A. 2010;107:10737–10742.
   PubMed Web of Science ®Google Scholar
• Otterson AG, Villalona-Calero AM, Sharma S, et al. Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs. Clin Cancer Res. 2007;13:1246–1252.
   PubMed Web of Science ®Google Scholar
• Otterson AG, Villalona-Calero AM, Hick W, et al. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non–small cell lung. Cancer Clin Cancer Res. 2010;16(8):2466–2473.
   PubMed Web of Science ®Google Scholar
• Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology. 2013;2:e26333.
   PubMed Web of Science ®Google Scholar
• Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008;133:528–538.
   PubMed Web of Science ®Google Scholar
• Achermann Y, Frauenfelder T, Obrist S, et al. A rare but severe pulmonary side effect of cetuximab in two patients. BMJ Case Rep. 2012;2012:bcr0320125973.
   PubMedGoogle Scholar
• Lai JI, Wang WS, Lai YC, et al. Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy. Int J Clin Pharmacol Ther. 2010;48:425–428.
   PubMed Web of Science ®Google Scholar
• Ahamed E, Mauri FA, Pakter G, et al. Trastuzumab: unusual responses and toxicities. Future Oncol. 2009;5:779–784.
   PubMed Web of Science ®Google Scholar
• Abulkhair O, El Melouk W. Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer. Case Rep Oncol. 2011;4:186–191.
   PubMedGoogle Scholar
• Pepels MJ, Boomars KA, van Kimmenade R, et al. Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Res Treat. 2009;113:609–612.
   PubMed Web of Science ®Google Scholar
• Guan M, Zhou YP, Su JL, et al. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int. 2015;2015:428169.
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Olivotto IA, Parulekar WR, et al. regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307–316.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Takahashi W, Haga A, et al. Radiation pneumonitis after stereotactic radiation therapy for lung cancer. World J Radiol. 2014;6:708–715.
   PubMedGoogle Scholar
• Han S, Gu F, Lin G, et al. Analysis of clinical and dosimetric factors influencing radiation-induced lung injury in patients with lung cancer. J Cancer. 2015;6:1172–1178.
   PubMed Web of Science ®Google Scholar
• Hassaballa HA, Cohen ES, Khan AJ, et al. Positron emission tomography demonstrates radiation-induced changes to nonirradiated lungs in lung cancer patients treated with radiation and chemotherapy. Chest. 2005;128:1448–1452.
   PubMed Web of Science ®Google Scholar
• Conway JL, Long K, Ploquin N, et al. Unexpected symptomatic pneumonitis following breast tangent radiation: a case report. Cureus. 2015;7:e363.
   Google Scholar
• Khalil AA, Hoffmann L, Moeller DS, et al. New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy. Acta Oncol. 2015;54:1343–1349.
   PubMed Web of Science ®Google Scholar
• Lee YH, Kim YS, Lee SN, et al. Interstitial lung change in pre-radiation therapy computed tomography is a risk factor for severe radiation pneumonitis. Cancer Res Treat. 2015;47:676–686.
   PubMed Web of Science ®Google Scholar
• Williams JP, Johnston CJ, Finkelstein JN. Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction? Curr Drug Targets. 2010;11:1386–1394.
   PubMed Web of Science ®Google Scholar
• Jeba J, Isiah R, Subhashini J, et al. Radiation pneumonitis after conventional radiotherapy for breast cancer: a prospective study. J Clin Diagn Res. 2015;9:XC01–XC05.
   Google Scholar
• Kimura T, Togami T, Takashima H, et al. Radiation pneumonitis in patients with lung and mediastinal tumours: a retrospective study of risk factors focused on pulmonary emphysema. Br J Radiol. 2012;85(1010):135–141.
   PubMed Web of Science ®Google Scholar
• Awad R, Nott L. Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: case report and literature review. Asia Pac J Clin Oncol. 2016;12:91–95.
   PubMed Web of Science ®Google Scholar
• Clark D, Gauchan D, Ramaekers R, et al. Radiation recall pneumonitis during systemic treatment with everolimus. Oncol Res. 2014;22:321–324.
   PubMed Web of Science ®Google Scholar
• Ochiai S, Nomoto Y, Yamashita Y, et al. Radiation-induced organizing pneumonia after stereotactic body radiotherapy for lung tumor. J Radiat Res. 2015;56:904–911.
   PubMed Web of Science ®Google Scholar
• Murofushi KN, Oguchi M, Gosho M, et al. Radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome in breast cancer patients is associated with age. Radiat Oncol. 2015;10:103.
   PubMedGoogle Scholar
• De Jonge E, Bos MM. Patients with cancer on the ICU: the times they are changing. Crit Care. 2009;13:122.
   PubMed Web of Science ®Google Scholar
• Lyngaa T, Christiansen CF, Nielsen H, et al. Intensive care at the end of life in patients dying due to non-cancer chronic diseasesversus cancer: a nationwide study in Denmark. Crit Care. 2015;19:413.
   PubMed Web of Science ®Google Scholar
• Mokart D, Lambert J, Schnell D, et al. Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leuk Lymphoma. 2013;54:1724–1729.
   PubMed Web of Science ®Google Scholar
• Lecuyer L, Chevret S, Thiery G, et al. The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med. 2007;35:808–814.
   PubMed Web of Science ®Google Scholar
• Xia R, Wang D. Intensive care unit prognostic factors in critically ill patients with advanced solid tumors: a 3-year retrospective study. BMC Cancer. 2016;16:188.
   PubMedGoogle Scholar
• de Montmollin E, Tandjaoui-Lambiotte Y, Legrand M, et al. Outcomes in critically ill cancer patients with septic shock of pulmonary origin. Shock. 2013;39:250–254.
   PubMed Web of Science ®Google Scholar
• Azoulay E, Schlemmer B. Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Med. 2006;32:808–822.
   PubMed Web of Science ®Google Scholar
• Saillard C, Mokart D, Lemiale V, et al. Mechanical ventilation in cancer patients. Minerva Anestesiol. 2014;80:712–725.
   PubMed Web of Science ®Google Scholar
• Soares M, Salluh JIF, Depuydt PO. Mechanical ventilation in patients with haematological malignancies. In: Azoulay E, editor. Pulmonary involvement in patients with haematological malignancies. Milan: Springer; 2011. p. 597–606.
   Google Scholar
• Soares M, Salluh JI, Spector N, et al. Characteristics and outcomes of cancer patients requiring mechanical ventilatory support for >24 hrs. Crit Care Med. 2005;33:520–526.
   PubMed Web of Science ®Google Scholar
• Mosier JM, Sakles JC, Whitmore SP, et al. Failed noninvasive positive-pressure ventilation is associated with an increased risk of intubation-related complications. Ann Int Care. 2015;5:4.
   PubMedGoogle Scholar
• Meeder AM, Tjan DHT, van Zanten ARH. Noninvasive and invasive positive pressure ventilation for acute respiratory failure in critically ill patients: a comparative cohort study. J Thorac Dis. 2016;8:813–825.
   PubMed Web of Science ®Google Scholar
• Chacur FH, Vilella Felipe LM, Fernandes CG, et al. The total face mask is more comfortable than the oronasal mask in noninvasive ventilation but is not associated with improved outcome. Respiration. 2011;82:426–430.
   PubMed Web of Science ®Google Scholar
• Papazian L, Corley A, Hess D, et al. Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review. Intensive Care Med. 2016. [cited 11 Mar 2016]; DOI:10.1007/s00134-016-4277-8.
   Google Scholar
• Nishimura M. High-flow nasal cannula oxygen therapy in adults. J Intensive Care. 2015;3:15.
   PubMed Web of Science ®Google Scholar
• Peters SG, Holets SR, Gay PC. High-flow nasal cannula therapy in do-not-intubate patients with hypoxemic respiratory distress. Respir Care. 2013;58:597–600.
   PubMed Web of Science ®Google Scholar
• Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med. 1997;156:196–200.
   PubMed Web of Science ®Google Scholar
• Kottmann RM, Kelly J, Lyda E, et al. Bronchoscopy with bronchoalveolar lavage: determinants of yield and impact on management in immunosuppressed patients. Thorax. 2011;66:823.
   PubMed Web of Science ®Google Scholar
• Kasow KA, King E, Rochester R, et al. Diagnostic yield of bronchoalveolar lavage is low in allogeneic haematopoietic stem cell recipients receiving immunosuppressive therapy or with acute graft-versus-host disease: the St. Jude experience, 1990–2002. Biol Blood Marrow Transplant. 2007;13:831–837.
   PubMed Web of Science ®Google Scholar
• Crocket JA, Chaput MR, Lien DC. Fibreoptic bronchoscopy in the diagnosis of pulmonary disease in the immunocompromised host in northern Alberta. Can J Infect Dis. 1995;6:286–290.
   PubMedGoogle Scholar
• Brownback KR, Thomas LA, Simpson SQ. Role of bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in immunocompromised patients. Curr Opin Infect Dis. 2014;27:322–328.
   PubMed Web of Science ®Google Scholar
• Damiani C, Le Gal S, Goin N, et al. Usefulness of (1,3) ß-D-glucan detection in bronchoalveolar lavage samples in Pneumocystis pneumonia and Pneumocystis pulmonary colonization. J Mycol Med. 2015;25:36–43.
   PubMed Web of Science ®Google Scholar
• Xirogianni A, Tsolia M, Voyiatzi A, et al. Diagnosis of upper and lower respiratory tract bacterial infections with the use of multiplex PCR assays. Diagnostics. 2013;3:222–231.
   Google Scholar
• Mok JH, Eom JS, Jo EJ, et al. Clinical utility of rapid pathogen identification using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in ventilated patients with pneumonia: A pilot study. Respirology. 2016;21:321–328.
   PubMed Web of Science ®Google Scholar
• Azoulay E, Mokart D, Rabbat A, et al. Diagnostic bronchoscopy in haematology and oncology patients with acute respiratory failure: prospective multicenter data. Crit Care Med. 2008;36:100–107.
   PubMed Web of Science ®Google Scholar
• Murgu S, Langer S, Colt H. Bronchoscopic intervention obviates the need for continued mechanical ventilation in patients with airway obstruction and respiratory failure from inoperable non-small-cell lung cancer. Respiration. 2012;84:55–61.
   PubMed Web of Science ®Google Scholar
• Ma SQ, Lin Y, Ying HY, et al. Solid malignancies complicated with pulmonary embolism: clinical analysis of 120 patients. Chin Med J (Engl). 2010;123:29–33.
   PubMed Web of Science ®Google Scholar
• Righini M, Perrier A, De Moerloose P, et al. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost. 2008;6:1059–1071.
   PubMed Web of Science ®Google Scholar
• Alexander M, Wolfe R, Ball D, et al. OC-05 – D-Dimer, fibrinogen and TEG-MA predict thromboembolism in non-small cell lung cancer – interim results from a prospective cohort study. Thromb Res. 2016;140(Suppl 1):S170.
   Google Scholar
• Shim H, Kim WS, Kim YW, et al. Successful management of pulmonary and inferior vena cava tumor embolism from renal cell carcinoma. Korean J Thorac Cardiovasc Surg. 2012;45:323–325.
   PubMedGoogle Scholar
• Kim S, Oh IJ, Park SY, et al. Corticosteroid therapy against treatment-related pulmonary toxicities in patients with lung cancer. J Thorac Dis. 2014;6:1209–1217.
   PubMed Web of Science ®Google Scholar
• Ochoa R, Bejarano PA, Glück S, et al. Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep. 2012;6:413.
   PubMedGoogle Scholar
• Magaña E, Crowell RE. Radiation pneumonitis successfully treated with inhaled corticosteroids. South Med J. 2003;96:521–524.
   PubMed Web of Science ®Google Scholar
• Ding X, Ji W, Li J, et al. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer. Radiat Oncol. 2011;6:24.
   PubMed Web of Science ®Google Scholar
• Cornelissen R, Senan S, Antonisse IE, et al. Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma. Radiat Oncol. 2007;2:2.
   PubMed Web of Science ®Google Scholar
• Stover DE, Mangino D. Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia? Chest. 2005;128:3611–3617.
   PubMed Web of Science ®Google Scholar
• Gerhardt SG, McDyer JF, Girgis RE, et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168:121–125.
   PubMed Web of Science ®Google Scholar
• Epler GR, Kelly EM. Systematic review of postradiotherapy bronchiolitis obliterans organizing pneumonia in women with breast cancer. Oncologist. 2014;19:1216–1226.
   PubMed Web of Science ®Google Scholar
• Cai M, Bonella F, Dai H, et al. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology. 2013;218:930–937.
   PubMed Web of Science ®Google Scholar
• Zhuang H, Yuan Z, Chang JY, et al. Radiation pneumonitis in patients with non–small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J Thorac Oncol. 2014;9:882–885.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2015;15(171):388–416.
   Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52:e56–93.
   PubMedGoogle Scholar
• Frei CR, Attridge RT, Mortensen EM, et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther. 2010;32:293–299.
   PubMed Web of Science ®Google Scholar
• Frei CR, Koeller JM, Burgess DS, et al. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. Pharmacotherapy. 2003;23:1167–1174.
   PubMed Web of Science ®Google Scholar
• Bebear C. Editorial commentary: infections due to macrolide-resistant Mycoplasma pneumoniae: now what? Clin Infect Dis. 2012;55:1650–1651.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Bianchi W, Ohnmeiss H. Treatment of infections in non-neutropenic patients with cancer, AIDS, or renal transplant using ciprofloxacin. Chemioterapia. 1988;7:164–168.
   PubMedGoogle Scholar
• Nseir S, Di Pompeo C, Soubrier S, et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med. 2005;33:283–289.
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis. 2000;19:915–925.
   PubMed Web of Science ®Google Scholar
• Joo EJ, Kang CI, Ha YE, et al. Clinical predictors of Pseudomonas aeruginosa bacteremia among Gram-negative bacterial infections in non-neutropenic patients with solid tumor. J Infect. 2011;63:207–214.
   PubMed Web of Science ®Google Scholar
• Raad I, Hachem R, Hanna H, et al. Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study. Ann Surg Oncol. 2001;8:179–186.
   PubMed Web of Science ®Google Scholar
• Ghannam DE, Rodriguez GH, Raad II, et al. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis. 2009;28:253–259.
   PubMed Web of Science ®Google Scholar
• Jenkins TC, Sakai J, Knepper BC, et al. Risk factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia. Acad Emerg Med. 2012;19:703–706.
   PubMed Web of Science ®Google Scholar
• Verhaegen J, Flamaing J, De Backer W, et al. Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009–2011. Euro Surveill. 2014;19:14–22.
   PubMedGoogle Scholar
• Woodhead M, Blasi F, Ewig S, et al. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–59.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36:612–620.
   PubMed Web of Science ®Google Scholar
• Lorenzo MJ, Moret I, Sarria B, et al. Lung inflammatory pattern and antibiotic treatment in pneumonia. Respir Res. 2015;16:15.
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Mckeever TM, Woodhead M, et al., British Thoracic Society. Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax. 2013;68:493–495.
   PubMed Web of Science ®Google Scholar
• McEvoy C, Micek ST, Reichley RM, et al. Macrolides are associated with a better survival rate in patients hospitalized with community-acquired but not healthcare-associated pneumonia. Surg Infect (Larchmt). 2014;15:283–289.
   PubMed Web of Science ®Google Scholar
• Thompson AM, Thomas SE, Schafers SJ, et al. The role of azithromycin in healthcare-associated pneumonia treatment. Clin Pharm Ther. 2015;40:517–524.
   Web of Science ®Google Scholar
• Cillóniz C, Gabarrús A, Ferrer M, et al. Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa. Chest. 2016;150:415–425.
   PubMed Web of Science ®Google Scholar
• Tennenberg AM, Davis NB, Wu SC, et al. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. Curr Med Res Opin. 2006;22:843–850.
   PubMed Web of Science ®Google Scholar
• Yayan J, Ghebremedhin B, Rasche K, et al. antibiotic resistance of pseudomonas aeruginosa in pneumonia at a Single University Hospital Center in Germany over a 10-year period. PloS One. 2015;10(10):e0139836.
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Renaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolones. Ann Med. 2014;46:512–529.
   PubMed Web of Science ®Google Scholar
• Park HS, Kim HJ, Seol MJ, et al. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother. 2006;50:2261–2264.
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol. 2015;10:1111–1123.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Izumikawa K, Morinaga Y, et al. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan. J Infect Chemother. 2013;19:291–298.
   PubMed Web of Science ®Google Scholar
• Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant pseudomonas aeruginosa. Clin Infect Dis. 2015;61:853–855.
   PubMed Web of Science ®Google Scholar
• Xiao AJ, Miller BW, Huntington JA, et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56:56–66.
   PubMed Web of Science ®Google Scholar
• Falcó V, Burgos J, Papiol E, et al. Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia. Expert Opin Investig Drugs. 2016;25(6):653–665.
   PubMed Web of Science ®Google Scholar
• Wenzler E, Gotfried MH, Loutit JS, et al. Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother. 2015;59:7232–7239.
   PubMed Web of Science ®Google Scholar
• Leem AY, Jung WJ, Kang YA, et al. Comparison of methicillin-resistant Staphylococcus aureus community-acquired and healthcare-associated pneumonia. Yonsei Med J. 2014;55:967–974.
   PubMed Web of Science ®Google Scholar
• Metersky ML, Frei CR, Mortensen EM. Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia. Respirology. 2016;21:157–163.
   PubMed Web of Science ®Google Scholar
• Rello J, Nieto M, Solé-Violán J, et al. Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective. Med Intensiva. 2016. [cited 2016 Apr 6]; DOI:10.1016/j.medin.2016.01.007.
   PubMedGoogle Scholar
• Shorr FA, Puzniak AL, Biswas P, et al. Predictors of clinical success in the treatment of patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Nosocomial Pneumonia (NP). PLoS One. 2015;10:e0131932.
   Google Scholar
• Lin PC, Wang BC, Kim R, et al. Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Taiwan. J Microbiol Immunol Infect. 2016;49:46–51.
   PubMedGoogle Scholar
• Moschovi M, Trimis G, Tsotra M, et al. Efficacy and safety of linezolid in immunocompromised children with cancer. Pediatr Int. 2010;52:694–698.
   PubMed Web of Science ®Google Scholar
• Cohen N, Mihu CN, Seo SK, et al. Haematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1337–1341.
   PubMed Web of Science ®Google Scholar
• Rello J, Rahav J, Scheeren T. A pooled analysis of clinical cure and mortality with ceftobiprole medocaril versus comparators in staphylococcal bacteraemia in complicated skin infections, and community- and hospital-acquired pneumonia. 2016. Abstract presented at 26th European congress of clinical microbiology and infectious diseases. Amsterdam (Netherlands). Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=31024
   Google Scholar
• May AK. an argument for the use of aminoglycosides in the empiric treatment of ventilator-associated pneumonia. Surg Infect (Larchmt). 2016;17(3):329–333.
   PubMed Web of Science ®Google Scholar
• Arnold HM, Sawyer AM, Kollef MH. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care. 2012;57:1226–1233.
   PubMed Web of Science ®Google Scholar
• Czosnowski QA, Wood GC, Magnotti LJ, et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy. 2009;29:1054–1060.
   PubMed Web of Science ®Google Scholar
• Gurjar M. Colistin for lung infection: an update. J Intensive Care. 2015;22(3):3.
   Google Scholar
• Liu D, Zhang J, Liu HX, et al. Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;46:603–609.
   PubMed Web of Science ®Google Scholar
• Abdellatif S, Trifi A, Daly F, et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016;6:26.
   PubMed Web of Science ®Google Scholar
• Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68:140–151.
   PubMed Web of Science ®Google Scholar
• Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57:1756–1762.
   PubMed Web of Science ®Google Scholar
• Heizmann WR, Löschmann PA, Eckmann C, et al. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Infection. 2015;43:37–43.
   PubMed Web of Science ®Google Scholar
• Shen F, Han Q, Xie D, et al. Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis. 2015;39:25–33.
   PubMed Web of Science ®Google Scholar
• Masur H, Brooks JT, Benson CA, et al. HIV Medicine Association of the Infectious Diseases Society of America. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:1308–1311.
   PubMed Web of Science ®Google Scholar
• Creemers-Schild D, Kroon FP, Kuijper EJ, et al. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study. Infection. 2016;44::291–299.
   PubMed Web of Science ®Google Scholar
• Lee SM, Cho YK, Sung YM, et al. A case of pneumonia caused by pneumocystis jirovecii resistant to trimethoprim-sulfamethoxazole. Korean J Parasitol. 2015;53:321–327.
   PubMed Web of Science ®Google Scholar
• Tu GW, Ju MJ, Xu M, et al. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients. Nephrology (Carlton). 2013;18:736–742.
   PubMed Web of Science ®Google Scholar
• Lee WS, Hsueh PR, Hsieh T, et al. Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia. J Microbiol Immunol Infect. 2016 [cited 2016 Mar 28]; DOI:10.1016/j.jmii.2016.03.008.
   Google Scholar
• Leentjens J, Kow M, van der Hoeven JG, et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med. 2013;187:1287–1293.
   PubMed Web of Science ®Google Scholar